Evaluating improvement interventions using routine data to support a learning health system:research design, data access, analysis and reporting by Weir, Christopher J et al.
                          Weir, C. J., Heazell, A., Whyte, S., & Norman, J. E. (2020). Evaluating
improvement interventions using routine data to support a learning health
system: research design, data access, analysis and reporting. BMJ Quality
and Safety. https://doi.org/10.1136/bmjqs-2019-010068
Peer reviewed version
Link to published version (if available):
10.1136/bmjqs-2019-010068
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via BMJ at https://qualitysafety.bmj.com/content/early/2020/02/25/bmjqs-2019-010068. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
 1 
 
Evaluating improvement interventions using routine data to support a learning health system: 
research design, data access, analysis and reporting   
 
Running title: Improvement intervention evaluations  
 
*Christopher J Weir PhD1, Alexander E P Heazell PhD2,3, Sonia Whyte MSc4, Jane E Norman MD4,5 
 
1 Edinburgh Clinical Trials Unit, Centre for Population Health Sciences, Usher Institute of Population 
Health Sciences and Informatics, the University of Edinburgh, Nine Edinburgh BioQuarter, 9 Little 
France Road, Edinburgh, EH16 4UX, UK   
2 Tommy’s Maternal and Fetal Health Research Centre, School of Medical Sciences, Faculty of 
Biology, Medicine and Health, University of Manchester, Manchester, UK 
3 St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester 
Academic Health Science Centre, Manchester, UK 
4 Tommy’s Centre for Maternal and Fetal Health, MRC Centre for Reproductive Health, Queen’s 
Medical Research Institute, Edinburgh, EH16 4TY, UK 
5 Faculty of Health Sciences, University of Bristol, Bristol, UK. 
 
* Corresponding author, Christopher.Weir@ed.ac.uk, telephone 0131 651 9957 
 
Contribution to authorship 
CJW drafted this Viewpoint; CJW, AEPH, SW and JEN critically reviewed and edited its content. 
 2 
 
Disclosure of interests 
All authors were collaborators on the AFFIRM clinical trial which is cited in this Commentary; AEPH 
was a lead investigator on the SPIRE study. 
Funding 
CJW was funded in this work by NHS Lothian via the Edinburgh Clinical Trials Unit. The AFFIRM study 
was investigator-initiated and funded by the Chief Scientist Office, Scottish Government (CZH/4/882), 
Tommy's, and Sands. SPIRE was funded by NHS England.  
Word count  2376 
Details of ethics approval 
AFFIRM received a favourable opinion from Scotland A Research Ethics Committee (Ref 13/SS/0001) 
SPIRE received a favourable opinion from West Midlands, Edgbaston Research Ethics Committee (Ref 
17/WM/0197).   
 3 
 
Introduction: learning health systems 
Friedman and colleagues1 outline a vision of the learning health system, founded on the sharing of 
data and achieved through alignment of information technology, advanced analytics and clinical 
expertise. The Institute of Medicine2 recognises the potential of the learning health system to 
generate new information automatically during the delivery of healthcare, offering continual 
opportunities to improve healthcare processes to the benefit of public health. The learning health 
system is promoted as a mechanism to accelerate the adoption of effective treatments into clinical 
practice, shortening the extended delay3 from publication of research findings to implementation.  
Furthermore, it harbours the ambition to deliver personalised medicine to each service user, rather 
than the systematic provision of identical care to groups of patients who share the same 
characteristics. Worldwide escalating costs in healthcare provision due to demographic changes, 
compounded by ongoing use of ineffective tests and treatments, make it critically important to 
harness the efficiency gains of a learning health system. Of its many potential characteristics, one 
distinct attribute of the learning health system is to enable efficient investigation of whether strategies 
promoting implementation of best practice (such as educational initiatives or care bundles) actually 
work. A systematic review identifying a low frequency of reports on the evaluation and impact of 
learning health systems4 prompted us here to reconsider the central requirements for evaluation of 
improvement interventions within the learning health system.   
Here, we reflect on two recent implementation studies, both utilising efficiencies of the learning 
health system (minimising data acquisition and relying heavily on data acquisition from existing 
medical records), to illustrate the key issues arising when incorporating this type of research into the 
learning health system. In this paper we argue that the presence of infrastructure which facilitates 
data sharing, combined with appropriate research design, analysis and reporting, are essential 
elements in the evaluation of healthcare improvement interventions. 
Data, research design and the learning health system 
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Ready access to routine data in the learning health system is a priority for commissioners of 
implementation research investigating system-wide healthcare interventions and researchers 
performing those evaluations. In turn, this becomes an important consideration for those configuring 
new or updated electronic health record systems. Here, using both the AFFIRM trial (Can Promoting 
Awareness of Fetal movements and Focussing Interventions Reduce fetal Mortality - a stepped wedge 
cluster randomised trial)5 and the SPIRE project (Saving Babies' Lives Project Impact and Results 
Evaluation)6 as case studies, we elucidate key challenges in three areas central to the conduct of such 
research at scale:  data access; research design; and analysis and reporting. We conclude with 
recommendations for research commissioners, researchers and managers of healthcare information 
systems to enable the benefits of a learning health system in evaluating improvement interventions 
to be achieved. 
AFFIRM and SPIRE 
The AFFIRM trial 5 evaluated a package of care aimed at reducing stillbirth. The complex intervention 
evaluated in AFFIRM (in over 400,000 women) combined strategies for increasing awareness among 
pregnant women of the need to report decreased fetal movements (DFM) promptly, with a structured 
management plan to identify fetal compromise and achieve timely delivery in suspected and 
confirmed cases of DFM. SPIRE 6 aimed to determine whether the Saving Babies Lives Care Bundle 
reduced the occurrence of stillbirth by applying best practice to four components of maternity care. 
Its evaluation included more than 95,000 deliveries per year in 19 secondary and tertiary maternity 
units covering 9 local authorities in England. Both AFFIRM and SPIRE were pragmatic trials, applying 
“real world” implementation at scale, and evaluating outcomes through the use of routinely collected 
data. 
Data access 
The first challenge for studies such as AFFIRM and SPIRE arises from the use of routinely collected 
data. The research team relies on the required measurements being available and accurately 
 5 
 
recorded. For AFFIRM, the Scottish Birth Record, Maternal Inpatient and Day Case Records contained 
all the necessary data for sites in Scotland on inpatient care, mother and baby characteristics, and 
pregnancy and baby outcomes. Substantial data management input was then needed to map separate 
data sources from study sites in England, Wales, Northern Ireland and the Republic of Ireland onto a 
common database (409,175 women in total) stored securely in the safe haven at National Health 
Service (NHS) National Services Scotland. Not all desirable information was routinely available; for 
example the frequency with which investigations (such as cardiotocography) were used (to assess 
fidelity of implementation of the intervention) and the results of those examinations had to be 
gathered separately in site audits.  
The quality of routinely collected data is further complicated by variation in nature of recording and 
coding of individual activities e.g. ultrasound scan to measure fetal growth, such that in SPIRE only the 
overall average number of ultrasound scans performed could be calculated rather than just those 
relevant to the area of study. These limitations to the nature and scope of routinely collected data 
disproportionately affect process measures (for instance, the number of women attending with DFM) 
as these are less likely to be recorded than outcomes (for example, stillbirth). As a result, intervention 
fidelity can be measured at an aggregate level (ward or healthcare facility) but not for individual 
patients.7  In some instances, dependent on the nature of the intervention being evaluated, such 
cluster-level assessment of fidelity may be all that is required. Importantly, clinical coding dictionaries 
often do not include items for the presence of significant symptoms such as DFM. The fundamental 
importance of data management issues is reflected in the RECORD8 reporting guidance for research 
using routinely collected data.  
Access permissions are also key: in the European Union, the General Data Protection Regulation9 
incorporates a “legitimate interest” criterion which is currently being applied to support the use, in 
the presence of appropriate information governance safeguards, of routine data for research. Ease of 
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access to relevant and interpretable routine data is a fundamental requirement of any learning health 
system. 
Research design 
The second feature concerns the importance of advance planning of study design in the evaluation of 
improvement interventions. Prospective planning of the implementation and evaluation of the 
intervention enabled AFFIRM to set up a stepped-wedge cluster-randomised trial design10 whereas 
SPIRE took the form of a natural experiment as its evaluation was only planned after the development 
and introduction of the intervention in early adopter sites.  
Stepped-wedge design trials (Figure 1) commence with all of the clusters delivering treatment as 
usual.  At regular pre-specified intervals each cluster (or group of clusters) implements the 
intervention and maintains this for the remainder of the trial.  By the final time interval all clusters 
have adopted the intervention.  Randomisation determines the time point at which each cluster 
commences the intervention.   
Stepped-wedge designs are conceptually useful in enabling an empirical randomised evaluation of an 
intervention which is intended to be rolled out across an entire health system. Non-randomised 
designs, based on real-world evidence alone, provide an alternative evaluation framework. While 
some advocate the use of causal inference in non-randomised designs, consensus is lacking and 
approaches such as propensity scoring to address confounding require sensitivity analyses to provide 
further assurance on their validity.11 The confounding of intervention effects with time in non-
randomised simple before-and-after designs10 is also present in stepped-wedge designs. Time effects 
may be adjusted for in the analysis of stepped-wedge trials to reduce such confounding, although this 
requires the reasonably strong assumption that the underlying time trend is the same for all clusters.  
Interrupted time series analysis may be applied to observational study designs; while this offers 
another candidate approach to evaluating service-level interventions, it is also vulnerable to 
confounding.  Furthermore it assumes a fixed time point at which change happens: as was found in 
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SPIRE,6 this may not reflect the reality of introducing a complex intervention at service level. The key 
advantage of the stepped-wedge randomised design over non-randomised before-and-after designs 
is that it enables a contemporary comparison between clusters which have, and have not, 
implemented the intervention. 
All designs which randomise clusters rather than individual participants incur a penalty which inflates 
the sample size required. It is notable that for a given number of participants per cluster, stepped-
wedge designs require a smaller number of clusters (are more efficient) than parallel group cluster 
trials; however, this greater efficiency is lost where the within-cluster correlation of outcomes (the 
“intra-cluster correlation coefficient”) is low.12      
Depending on the nature and risk profile of the intervention being investigated, such cluster trials may 
not require individual informed consent from participants,13 which potentially enhances study 
efficiency and representativeness of the trial population.  Nevertheless, recommendations on 
informed consent in the Ottawa statement14 emphasise that consent should be sought unless a waiver 
is clearly justified.  Technical understanding of sample size requirements15 and optimal design 
configurations16 has developed for stepped-wedge trials.  
Practical challenges include factors outside the control of the researcher, for example the closure of 
study sites; and, as encountered in AFFIRM, the dropout of sites, post-randomisation, for reasons such 
as the perceived costs of the intervention being studied. Sites must also be willing to agree to the 
intervention at baseline and to defer implementation until the time point allocated in the 
randomisation sequence – mistimed implementation adversely impacts on study integrity.17 Such 
challenges emphasise the need to consider evaluation strategies concurrently with the development 
of interventions so that potential challenges can be identified and addressed. 
It is also important for understanding of the service-level impact of an intervention to study the 
varying degree to which sites implement the intervention. Quantitatively, we can establish the level 
of fidelity to the intervention in individual study sites. Qualitative studies enable further insight using 
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contextual information on the barriers to and facilitators of adoption of a complex intervention at 
scale. 
Evaluation designs which appropriately address the above considerations of precision (sample size), 
bias (time confounding) and the influence of mediating and moderating factors on intervention 
effectiveness are essential to facilitate learning in a health system.   
Analysis and reporting 
Finally, issues arise relating to statistical analysis and reporting. In AFFIRM, the stillbirth primary 
outcome was a rare event, with an expected frequency of about 0.44%.  This, together with the multi-
level models used to analyse data from a stepped-wedge design, required a sample size of several 
hundred thousand. Indeed, for some research questions several million participants will be needed.18 
Another statistical challenge when using routine data, which cannot be subjected to conventional 
clinical trial data querying, is missing data.  The missing data handling techniques being used should 
be pre-specified and the further assumptions they make will need to be justified and tested in 
sensitivity analyses. 
Two further statistical issues arise due to features of the stepped-wedge design. First, the confounding 
between time and intervention effect requires adjustment for secular trends, using assumptions such 
as similarity of time effects across clusters which may be difficult to verify empirically. Secondly, the 
intra-cluster correlation coefficient may vary over time or differ between treatment as usual and 
intervention.  While all of these statistical issues can be accommodated in the analysis, each in turn 
adds complexity to the model and requires a further layer of assumptions to be made and verified.    
Final reporting also requires careful consideration for trial designs where informed consent has not 
been sought.  For analyses of routine data performed within a secure safe haven environment, 
disclosure checking must be applied19, to ensure none of the resulting statistical outputs (tables, 
graphics or regression modelling) would potentially identify an individual. 
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The final requirements for evaluation of improvement interventions in the learning health system are 
therefore the tailoring of statistical analysis to be fit for purpose; and a reporting process which 
protects privacy in order to maintain trust in the use of routine healthcare data to inform service 
improvements.  
Recommendations 
Notwithstanding the challenges outlined above, the benefits of using routine data for evaluation of 
improvement as part of a learning healthcare system vastly outweigh the drawbacks. Healthcare 
technologies and needs are continually evolving, and the cost of healthcare ever spiralling upwards: 
to fail to innovate or to innovate without proper evaluation is at best lazy and at worst unethical. A 
learning healthcare approach allows evaluation at scale, for modest costs. Based on our experience 
with AFFIRM and SPIRE, we suggest some recommendations for clinical data champions, for 
researchers and commissioners of research, and for policy makers. Our recommendations cover 
routine data access, study design, and statistical analysis and reporting:  
Accessing routinely collected data   Those configuring or updating healthcare information 
systems should strive to establish unified electronic health records where such a facility is currently 
absent, since clinical audit is time consuming and resource intensive compared to directly accessing 
data via electronic health records. For example, in SPIRE 1,658 case notes were audited, 2,230 women 
responded to a questionnaire and 1,064 health professionals completed a survey.  It is also vital that 
information governance of electronic health records systems should facilitate secure access to data 
for research and incorporate a process for timely disclosure checking of research outputs to protect 
the anonymity of patients.  
Research study design  Commissioners of improvement research should endorse the use of 
randomised designs such as the stepped-wedge trial to enable empirical evaluation of healthcare 
system-wide interventions.  Given the likely variations in implementation of an intervention across 
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different sites, the randomised trial should be supported by a quantitative and qualitative process 
evaluation.  
Statistical analysis and reporting Researchers conducting trials using routinely collected data 
should incorporate a pre-specified and fully justified plan of the missing data handling methods to be 
used, which will require appraisal of the methods of data collection and development of an 
understanding of possible reasons why each data item might be missing.  Robustness of the statistical 
model being fitted should be verified by testing its assumptions in sensitivity analyses.  Researchers 
should also structure their data management and reporting to take account of the RECORD guidance8 
in order to support research transparency and optimise the interpretability and reproducibility of the 
findings.  
Conclusions 
As shown in AFFIRM and other studies using remote follow-up via electronic health records, the 
conduct of efficient randomised evaluations of interventions at scale generates robust evidence to 
support improvement in a learning health system. Such trials depend on appropriate infrastructure 
(safe haven access to routine data), study design (stepped-wedge trial) and analysis and reporting 
methods. Together, these have the potential to enable society to realise the benefits of a learning 
health system. 
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Figure 1 The stepped-wedge trial design 
Example stepped-wedge trial design. Initially (month 1) no clusters have implemented the 
intervention.  In month 2 a cluster (number 4) is randomly selected to implement the intervention. 
This process continues, one randomly selected cluster implementing the intervention each month, 
until by the end of the trial all eight clusters have adopted the intervention.    
